{
    "symbol": "ALPN",
    "quarter": 3,
    "year": 2022,
    "date": "2022-11-14 19:09:06",
    "content": " We are now operationalizing, a near-term broad development plan for ALPN-303 in multiple indications with the most profitable studies to begin in a renal basket, as well as the hematology basket was anticipated data from the studies by the end of this year. In closing, our best-in-class profile for ALPN-303 and our cash runway of three plus years, we believe we have made a strong foundation to launch to the next phase of growth for Alpine, as we executed on our ambitious drug development plans in a broad range of B cell mediated autoimmune and inflammatory diseases."
}